Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
Changes in lipids and lopinavir plasma concentrations were examined in 40 HIV-patients exposed to lopinavir/ritonavir 400/100 mg BID, formulated as tablets and as capsules. Triglycerides and total/HDL-cholesterol ratio were significantly lower with tablets than with capsules. Lopinavir concentrations were higher with tablets than with capsules.
Morello
Judit
J
Department of Pharmacy, Hospital Carlos III, Madrid, Spain.
Soriano
Vincent
V
Blanco
Francisco
F
Rubio
Antonio J
AJ
Jiménez-Nácher
Inmaculada
I
Rodríguez-Nóvoa
Sonia
S
D000328:Adult; D002214:Capsules; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects; D013607:Tablets; D014280:Triglycerides / Q000097:blood
D002214:Capsules; D008076:Cholesterol, HDL; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013607:Tablets; D014280:Triglycerides; D061466:Lopinavir; D002784:Cholesterol; D019438:Ritonavir